Biopharma Investor ESG Communications Initiative
“A confirmation that we are on track with our strategic thinking on ESG.”
- Biopharma
The Biopharma Investor ESG Communications Initiative was set up to address the common concern of leading biopharma companies and investors for more effective and efficient communications about the sector’s environmental, social, and governance (ESG) topics.
The Challenge
Biopharma and investors alike recognize challenges in deciding which biopharma environmental, social and governance topics are strategically relevant in a forward-looking manner due to several factors:
- Fatigue over proliferation of competing ESG ratings, standards, and frameworks
- Confusion over score divergence and perceived transparency of ESG ratings
- Lack of consensus about effective and efficient communications
Consensus Oriented Dialog
The Initiative facilitates a sector-focused direct dialog between biopharma and investors, complemented by engagement with key sector stakeholders. The conversations seek to build understanding on the ESG topics specific to the sector, and provide useful insights to support biopharma companies in setting and implementing their individual ESG communications strategies with the investor community.
Over 150 executives from biopharma companies, investor organizations, as well as key stakeholder groups have engaged in discussions since 2018.
Forward-looking Resource
The Initiative insights are reflected in the Biopharma Investor ESG Communications Guidance, which has been updated every few years.
The Guidance is intended as a resource and a primer for biopharma, investors, as well as key sector stakeholders that would like to understand the biopharma sector’s ESG and sustainability landscape. It identifies the biopharma ESG topics of shared interest, and provides insights to inform strategic ESG communications. The Initiative and the Guidance acknowledges that each entity will need to adapt to their own unique strategy, business model and readiness.
Initiative Partners and Sponsors
Additional Participants
BeiGene, Boehringer Ingelheim, Chiesi, Eli Lilly, Roche, Ferring, Hikma, Ipsen, Jazz Pharmaceuticals, LEO Pharma, Organon, Regeneron, Sanofi, Takeda, UCB
Publications
Ongoing Dialogs
“Since the Initiative launched, more than 150 executives from biopharma and investor companies have engaged in direct dialogs. Discussions with key stakeholder groups are ongoing, and the circle of contributors is expanding.”
BSRT Investor Network Participants
Thank you to everyone from the organizations that have contributed to the dialog.
